BLI 400

Drug Profile

BLI 400

Alternative Names: BLI400; BLI400 Laxative

Latest Information Update: 04 Jul 2016

Price : $50

At a glance

  • Originator Braintree Laboratories
  • Class Laxatives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Constipation

Most Recent Events

  • 01 Jun 2016 Braintree Laboratories initiates two phase III trials for Constipation (In adults) in USA (PO) (NCT02819297; NCT02819310)
  • 01 Dec 2015 Phase-II clinical trials in Constipation (In adolescents) in USA (PO) (NCT02665728)
  • 01 Nov 2015 Braintree Laboratories completes a phase III trial in Constipation (In adults) in USA (PO) (NCT02481947)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top